p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Autor: Hardwick NR; Department of Experimental Therapeutics, Beckman Research Institute, Duarte, California., Frankel P; Division of Biostatistics, Beckman Research Institute, Duarte, California., Ruel C; Division of Biostatistics, Beckman Research Institute, Duarte, California., Kilpatrick J; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California., Tsai W; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California., Kos F; Department of Experimental Therapeutics, Beckman Research Institute, Duarte, California., Kaltcheva T; Department of Experimental Therapeutics, Beckman Research Institute, Duarte, California., Leong L; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California., Morgan R; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California., Chung V; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California., Tinsley R; Clinical Trials Office, City of Hope National Medical Center, Duarte, California., Eng M; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California., Wilczynski S; Department of Pathology, City of Hope National Medical Center, Duarte, California., Ellenhorn JDI; Cedars-Sinai Medical Center, Los Angeles, California., Diamond DJ; Department of Experimental Therapeutics, Beckman Research Institute, Duarte, California. ddiamond@coh.org., Cristea M; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Mar 15; Vol. 24 (6), pp. 1315-1325. Date of Electronic Publication: 2018 Jan 04.

Analogue peptides for the immunotherapy of human acute myeloid leukemia.

Autor: Hofmann S; Third Clinic for Internal Medicine, University of Ulm, Ulm, Germany., Mead A; Department of Life Sciences, University of Bedfordshire, Park Square, Luton, LU1 3JU, UK., Malinovskis A; Department of Life Sciences, University of Bedfordshire, Park Square, Luton, LU1 3JU, UK., Hardwick NR; Division of Translational Vaccine Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.; Department of Haematological Medicine, Guy's, King's & St. Thomas' School of Medicine, The Rayne Institute, King's College London, 123 Coldharbour Lane, London, UK., Guinn BA; Department of Life Sciences, University of Bedfordshire, Park Square, Luton, LU1 3JU, UK. barbara.guinn@beds.ac.uk.; Department of Haematological Medicine, Guy's, King's & St. Thomas' School of Medicine, The Rayne Institute, King's College London, 123 Coldharbour Lane, London, UK. barbara.guinn@beds.ac.uk.; Cancer Sciences Unit, Southampton University Hospitals Trust, University of Southampton, Southampton, UK. barbara.guinn@beds.ac.uk.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2015 Nov; Vol. 64 (11), pp. 1357-67. Date of Electronic Publication: 2015 Oct 05.

Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.

Autor: Aloysius MM; Section of Surgery, Biomedical Research Unit, Nottingham Digestive Diseases Centre, University of Nottingham, UK. mark.aloysius@nottingham.ac.uk, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, Farzaneh F, Habib NA, Bhalla J, Hardwick NR, Satthaporn S, Sreenivasan T, El-Sheemy M, Eremin O

Publikováno v: Journal of translational medicine [J Transl Med] 2009 Mar 19; Vol. 7, pp. 18. Date of Electronic Publication: 2009 Mar 19.

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.

Autor: Song, Bin, Yang, Ping, Zhang, Shuyu

Publikováno v: Cancer Communications; Mar2024, Vol. 44 Issue 3, p297-360, 64p

TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.

Autor: Zhu, Kai-li, Su, Fei, Yang, Jing-ru, Xiao, Ruo-wen, Wu, Rui-yue, Cao, Meng-yue, Ling, Xiao-ling, Zhang, Tao

Publikováno v: Molecular Biology Reports; 2024, Vol. 51 Issue 1, p1-13, 13p